Table 2.
Univariate and multivariate analysis of OS in 148 patients with metastatic nasopharyngeal carcinoma.
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| p value | HR (95% CI) | p value | HR (95% CI) | |
| Gender (male/female) | 0.570 | 0.83 (0.435–1.581) | ||
| Age, years (<50/≥50) | 0.773 | 1.078 (0.646–1.801) | ||
| KPS (≥90/<90) | 0.411 | 0.765 (0.403–1.451) | ||
| Number of involved sites (one/multiple) | 0.179 | 1.369 (0.866–2.164) | ||
| Synchronous metastasis (yes/no) | 0.168 | 0.704 (0.427–1.160) | ||
| Liver metastasis (yes/no) | 0.802 | 0.942 (0.593–1.498) | ||
| Lung metastasis (yes/no) | 0.389 | 1.219 (0.777–1.914) | ||
| Bone metastasis (yes/no) | 0.071 | 1.525 (0.965–2.411) | ||
| Smoking (yes/no) | 0.210 | 0.750 (0.478–1.177) | ||
| GPS (0/1/2) | <0.001∗ | 3.135 (2.309–4.256) | 0.001∗ | 2.137 (1.369–3.337) |
| CRP/Alb (<0.189/≥0.189) | 0.003∗ | 1.998 (1.253–3.185) | 0.024∗ | 1.867 (1.085–3.210) |
| Serum LDH, U/L (<212/≥212) | 0.006 | 1.880 (1.193–2.962) | 0.602 | 0.858 (0.483–1.524) |
| EBV-DNA, copies/mL (<4.82 × 104/≥4.82 × 104) | <0.001∗ | 4.554 (2.792–7.427) | 0.041∗ | 2.012 (1.027–3.941) |
| Chemotherapy regimen (PF/TP/TPF) | 0.644 | 0.922 (0.653–1.302) | ||
| Treatment response (CR + PR/PD + SD) | 0.005∗ | 1.984 (1.231–3.197) | 0.420 | 1.242 (0.734–2.101) |
| NLR (<5/≥5) | 0.017∗ | 2.039 (1.133–3.671) | 0.192 | 1.522 (0.810–2.858) |
| PLR (<152/≥152) | 0.002∗ | 2.450 (1.407–4.267) | 0.128 | 1.617 (0.870–3.003) |
| Hemoglobin, g/L (<11/≥11) | 0.585 | 1.172 (0.664–2.069) | ||
CRP/Alb: C-reactive protein/albumin ratio; KPS: Karnofsky Performance Score; GPS: Glasgow Prognostic Score; NLR: neutrophil to lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; LDH: lactate dehydrogenase; ∗p < 0.05.